Clinical Trial Update: A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update indicating GLB-001 is being studied in relapsed or refractory Acute Myeloid Leukemia and relapsed or refractory higher-risk Myelod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• GLB-001

Snippet

Sponsor: GluBio Therapeutics Inc. | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: RECRUITING